Literature DB >> 8180579

Ras gene point mutation is a rare event in premalignant tissues and malignant cells and tissues from oral mucosal lesions.

W A Yeudall1, L K Torrance, K A Elsegood, P Speight, C Scully, S S Prime.   

Abstract

Three series of biopsy specimens of premalignant and malignant oral lesions, together with seven human keratinocyte cultures, previously established from oral squamous cell carcinomas, were analysed for point mutation in exons 1 and 2 of the c-Ha-ras, c-Ki-ras and N-ras genes by direct nucleotide sequencing of DNAs amplified in the polymerase chain reaction (PCR). Only one out of 12 biopsy samples (8.3%), a well-differentiated carcinoma which was the latest in a series of floor of mouth lesions from 1 of the 3 patients studied, harboured a mutant c-Ha-ras gene, being heterozygous at codon 12 for a GGA-GTA change. One cell line (H357) showed heterozygosity in both exons 1 and 2 of c-Ha-ras, harbouring a GGT to AGT mutation over codon 13 and a CAG to CAA mutation over codon 61. The remaining six oral carcinoma cell lines (85.7%) were homozygous normal at both exons 1 and 2 of c-Ha-ras. All cell lines showed normal c-Ki-ras and N-ras loci. We conclude that ras gene mutation is an infrequent occurrence in the malignant progression of oral epithelial cells, despite the probable importance of chemical carcinogens in the aetiology of the disease. We emphasise the need to search for other cellular sequences which may be targets for chemical or viral carcinogens.

Entities:  

Mesh:

Year:  1993        PMID: 8180579     DOI: 10.1016/0964-1955(93)90012-4

Source DB:  PubMed          Journal:  Eur J Cancer B Oral Oncol        ISSN: 0964-1955


  7 in total

1.  Expression of ets-1 is not affected by N-ras or H-ras during oral oncogenesis.

Authors:  Eleftherios Vairaktaris; Georgios Papageorgiou; Spyridoula Derka; Panagiota Moulavassili; Emeka Nkenke; Peter Kessler; Stavros Vassiliou; Veronica Papakosta; Sofia Spyridonidou; Antonis Vylliotis; Andreas C Lazaris; Sofia Anagnostopoulou; Constantinos Mourouzis; Christos Yapijakis; Efstratios Patsouris
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-28       Impact factor: 4.553

Review 2.  Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck.

Authors:  P G Sacks
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

3.  The absence of Harvey ras mutations during development and progression of squamous cell carcinomas of the head and neck.

Authors:  L J Clark; K Edington; I R Swan; K A McLay; W J Newlands; L C Wills; H A Young; P W Johnston; R Mitchell; G Robertson
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

4.  Binding of TGF-beta1 latency-associated peptide (LAP) to alpha(v)beta6 integrin modulates behaviour of squamous carcinoma cells.

Authors:  G J Thomas; I R Hart; P M Speight; J F Marshall
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640

5.  Prevalence of K-RAS Codons 12 and 13 Mutations in Locally Advanced Head and Neck Squamous Cell Carcinoma and Impact on Clinical Outcomes.

Authors:  Eric Bissada; Olivier Abboud; Zahi Abou Chacra; Louis Guertin; Xiaoduan Weng; Phuc Félix Nguyen-Tan; Jean-Claude Tabet; Eve Thibaudeau; Louise Lambert; Marie-Lise Audet; Bernard Fortin; Denis Soulières
Journal:  Int J Otolaryngol       Date:  2013-04-30

6.  Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck.

Authors:  H Kiaris; D A Spandidos; A S Jones; E D Vaughan; J K Field
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

7.  Common oncogenic mutations are infrequent in oral squamous cell carcinoma of Asian origin.

Authors:  Sharifah Nurain Syed Zanaruddin; Pei San Yee; Seen Yii Hor; Yink Heay Kong; Wan Maria Nabillah Wan Abd Ghani; Wan Mahadzir Wan Mustafa; Rosnah Binti Zain; Stephen S Prime; Zainal Ariff Abd Rahman; Sok-Ching Cheong
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.